Eagle Pharmaceuticals, Inc. (1E6.F)

4,0200 0,0000 (0,00%) Börsenschluss: 08:18AM CEST

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard
Suite 315
Woodcliff Lake, NJ 07677
United States
201 326 5300
https://www.eagleus.com

Sektor(en): Healthcare
Branche: Drug Manufacturers - Specialty & Generic
Vollzeitmitarbeiter: 134

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Michael Graves	Interim Principal Executive Officer & Executive Chairman of the Board	148,73k	N/A	1963
Mr. Steven B. Ratoff	Interim CFO, Principal Accounting Officer & Director	92,96k	N/A	1943
Mr. Daniel O'Connor	Executive VP, Chief Strategy Officer & Head of Corporate Development	N/A	N/A	1980
Dr. Valentin R. Curt M.D.	Senior Vice President of Clinical Drug Development	N/A	N/A	N/A
Dr. Gaozhong Zhu Ph.D.	Senior Vice President of Pharmaceutical Development	N/A	N/A	N/A
Ms. Debra M. Hussain	Senior VP & Head of Commercial	N/A	N/A	N/A
Mr. Reed McClung	Executive Vice President of Oncology Business Development	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Corporate Governance

Eagle Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 10, Vorstand: 9, Shareholderrechte: 7, Kompensation: 3.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.